$AXSM
Axsome Therapeutics, Inc.

2022 Q2 Form 10-Q Financial Statement

#000095017022006901 Filed on May 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $8.820M $0.00 $0.00
YoY Change
Cost Of Revenue $982.8K
YoY Change
Gross Profit $7.837M
YoY Change
Gross Profit Margin 88.86%
Selling, General & Admin $31.16M $25.70M $18.83M
YoY Change 90.65% 128.48% 81.72%
% of Gross Profit 397.61%
Research & Development $15.79M $12.59M $13.78M
YoY Change 8.89% -24.17% -20.71%
% of Gross Profit 201.51%
Depreciation & Amortization $993.4K $36.64K $31.04K
YoY Change 12195.05% 340.02%
% of Gross Profit 12.68%
Operating Expenses $47.02M $38.29M $32.61M
YoY Change 52.42% 37.51% 17.53%
Operating Profit -$39.18M -$38.29M
YoY Change 37.51%
Interest Expense -$2.257M -$1.343M -$1.368M
YoY Change 57.15% -5.39% -6.93%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$41.44M -$39.63M -$33.98M
YoY Change 28.36% 35.45% 16.52%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$41.44M -$39.63M -$33.98M
YoY Change 28.36% 35.45% 16.5%
Net Earnings / Revenue -469.84%
Basic Earnings Per Share -$1.06 -$1.03
Diluted Earnings Per Share -$1.060M -$1.034M -$899.6K
COMMON SHARES
Basic Shares Outstanding 38.91M 38.48M 37.69M
Diluted Shares Outstanding 39.08M 38.32M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $73.39M $84.71M $86.47M
YoY Change -48.03% -48.57% -52.98%
Cash & Equivalents $73.39M $84.71M $86.47M
Short-Term Investments
Other Short-Term Assets $4.091M $2.122M $45.29K
YoY Change 838.82% 430.54% -54.71%
Inventory $10.32M
Prepaid Expenses
Receivables $16.17M
Other Receivables $0.00
Total Short-Term Assets $104.0M $86.83M $86.52M
YoY Change -26.6% -47.39% -52.99%
LONG-TERM ASSETS
Property, Plant & Equipment $1.302M $460.9K $283.8K
YoY Change 0.75% 520.25% 439.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $507.5K $322.9K $322.9K
YoY Change 59.89% 1.74% 1.74%
Total Long-Term Assets $76.58M $1.730M $1.267M
YoY Change 4657.02% -7.39% -39.94%
TOTAL ASSETS
Total Short-Term Assets $104.0M $86.83M $86.52M
Total Long-Term Assets $76.58M $1.730M $1.267M
Total Assets $180.6M $88.56M $87.79M
YoY Change 26.03% -46.94% -52.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.43M $12.60M $13.15M
YoY Change 67.34% -13.86% -2.63%
Accrued Expenses $17.19M $11.95M $9.916M
YoY Change 52.77% 68.37% 0.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $42.57M $24.55M $23.07M
YoY Change 86.19% 13.22% -1.59%
LONG-TERM LIABILITIES
Long-Term Debt $93.46M $49.31M $49.09M
YoY Change 91.19% 1.47% 1.59%
Other Long-Term Liabilities $29.33M $0.00
YoY Change 35729.97% -100.0%
Total Long-Term Liabilities $122.8M $49.31M $49.09M
YoY Change 151.19% 1.47% 1.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.57M $24.55M $23.07M
Total Long-Term Liabilities $122.8M $49.31M $49.09M
Total Liabilities $165.4M $73.86M $72.15M
YoY Change 130.22% 4.6% -0.26%
SHAREHOLDERS EQUITY
Retained Earnings -$448.8M -$409.2M
YoY Change 45.67% 46.77%
Common Stock $463.5M $424.8M
YoY Change 14.64% 8.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.20M $14.70M $15.63M
YoY Change
Total Liabilities & Shareholders Equity $180.6M $88.56M $87.79M
YoY Change 26.03% -46.94% -52.84%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$41.44M -$39.63M -$33.98M
YoY Change 28.36% 35.45% 16.5%
Depreciation, Depletion And Amortization $993.4K $36.64K $31.04K
YoY Change 12195.05% 340.02%
Cash From Operating Activities -$33.54M -$32.65M -$28.84M
YoY Change 32.09% 19.98% 40.27%
INVESTING ACTIVITIES
Capital Expenditures -$241.5K $213.7K $0.00
YoY Change 1179.6% 612.57% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$53.00M
YoY Change
Cash From Investing Activities -$53.24M -$213.7K $0.00
YoY Change 282048.7% 612.57% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $31.01M
YoY Change 407.02%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 75.46M 31.10M 690.5K
YoY Change 3729.64% 287.36% -66.96%
NET CHANGE
Cash From Operating Activities -33.54M -32.65M -28.84M
Cash From Investing Activities -53.24M -213.7K 0.000
Cash From Financing Activities 75.46M 31.10M 690.5K
Net Change In Cash -11.31M -1.765M -28.15M
YoY Change -51.73% -90.81% 52.24%
FREE CASH FLOW
Cash From Operating Activities -$33.54M -$32.65M -$28.84M
Capital Expenditures -$241.5K $213.7K $0.00
Free Cash Flow -$33.30M -$32.87M -$28.84M
YoY Change 31.24% 20.63% 40.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001579428
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-37635
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
AXSOME THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-4241907
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
22 Cortlandt Street
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
16th Floor
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10007
CY2022Q1 dei City Area Code
CityAreaCode
212
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
332-3241
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
CY2022Q1 dei Trading Symbol
TradingSymbol
AXSM
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38913550
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84707782
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86472854
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2122144
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
45286
CY2022Q1 us-gaap Assets Current
AssetsCurrent
86829926
CY2021Q4 us-gaap Assets Current
AssetsCurrent
86518140
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
460946
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
283846
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
946479
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
660162
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
322910
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
322910
CY2022Q1 us-gaap Assets
Assets
88560261
CY2021Q4 us-gaap Assets
Assets
87785058
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
12595112
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13149329
CY2022Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10987222
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9295180
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
967248
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
620675
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
24549582
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23065184
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49312665
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49089522
CY2022Q1 us-gaap Liabilities
Liabilities
73862247
CY2021Q4 us-gaap Liabilities
Liabilities
72154706
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38883445
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38883445
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37816794
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37816794
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
3888
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3782
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
463525522
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
424825655
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-448831396
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-409199085
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
14698014
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15630352
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
88560261
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87785058
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12585141
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16595689
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25703731
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11248372
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
38288872
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
27844061
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-38288872
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27844061
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
-1343439
CY2021Q1 us-gaap Investment Income Net
InvestmentIncomeNet
-1415909
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-39632311
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-29259970
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.03
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38323167
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37429450
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113792909
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3731097
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1913299
CY2021Q1 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
6115864
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-29259970
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
96293199
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15630352
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7598329
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
181637
CY2022Q1 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
31008601
CY2022Q1 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
88594
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-39632311
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
14698014
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-39632311
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-29259970
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7598329
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3731097
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
223143
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
276095
CY2022Q1 us-gaap Depreciation
Depreciation
36636
CY2021Q1 us-gaap Depreciation
Depreciation
8326
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
275063
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
262764
CY2022Q1 axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
-214807
CY2021Q1 axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
-275840
CY2022Q1 axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
2076858
CY2021Q1 axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
226933
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-554217
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1117695
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1692042
CY2021Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-2848723
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32652980
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27215489
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
213736
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29995
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-213736
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29995
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
31008601
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6115864
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
181637
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1913299
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
88594
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31101644
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8029163
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1765072
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-19216321
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86472854
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
183876453
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84707782
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
164660132
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1118750
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
1143750
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
561380
CY2022Q1 axsm Number Of Late Stage Product Candidates
NumberOfLateStageProductCandidates
4
CY2022Q1 axsm Share Price Not Less Than Three Day Volume Weighted Average Share Price Discount Rate
SharePriceNotLessThanThreeDayVolumeWeightedAverageSharePriceDiscountRate
20
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-448800000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock‑based compensation expense; the determination of the fair value of the warrants; the accounting for research and development costs; and the recoverability of the Company’s net deferred tax assets and related valuation allowance.</span></p>
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
84700000
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At March 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">, the majority of the Company’s cash was held by </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;"> financial institution and the amount on deposit was in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash.</span></p>
CY2022Q1 axsm Number Of Financial Institutions Holding Deposits
NumberOfFinancialInstitutionsHoldingDeposits
1
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2726847
CY2021Q4 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2416897
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2013040
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4050236
CY2022Q1 axsm Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
5856779
CY2021Q4 axsm Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
2442700
CY2022Q1 us-gaap Interest Payable Current
InterestPayableCurrent
390556
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
385347
CY2022Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10987222
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9295180
CY2022Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1123958
CY2021Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1143750
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
97860
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
143589
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2022Q1 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
804053
CY2021Q4 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
706407
CY2022Q1 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1491388
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1616885
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49312665
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49089522
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
8026818
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
41973182
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
885000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
105000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
990000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
22752
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
967248
CY2022Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
In January 2022, the Company entered into an agreement to extend the lease of 22 Cortlandt Street for a term of six months from August 1, 2022 through January 31, 2023.
CY2022Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
extend the lease of 22 Cortlandt Street for a term of six months from August 1, 2022 through January 31, 2023.
CY2022Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P6M
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-39632311
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-29259970
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38323167
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37429450
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.03
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6901937
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4705122
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
290769
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
286923
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M12D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
82434018
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.00
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
91000000.0
CY2022Q1 axsm Equity Instrument Voting Rights Per Share
EquityInstrumentVotingRightsPerShare
1
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5090377
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.89
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1223019
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
30.05
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
18015
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.08
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
67139
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
43.83
CY2022Q1 axsm Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
9212
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
53.10
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6219030
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.98
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
106188389
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6219030
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
28.98
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
106188389
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2932835
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.85
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
6169
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7598329
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3731097
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.43
CY2022Q1 axsm Warrants Issued In Period
WarrantsIssuedInPeriod
0
CY2022Q1 axsm Warrants Issued In Period Weighted Average Exercise Price
WarrantsIssuedInPeriodWeightedAverageExercisePrice
0
CY2022Q1 axsm Warrants Exercised In Period
WarrantsExercisedInPeriod
0
CY2022Q1 axsm Warrants Exercised In Period Weighted Average Exercise Price
WarrantsExercisedInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.43

Files In Submission

Name View Source Status
0000950170-22-006901-index-headers.html Edgar Link pending
0000950170-22-006901-index.html Edgar Link pending
0000950170-22-006901.txt Edgar Link pending
0000950170-22-006901-xbrl.zip Edgar Link pending
axsm-20220331.htm Edgar Link pending
axsm-20220331.xsd Edgar Link pending
axsm-20220331_cal.xml Edgar Link unprocessable
axsm-20220331_def.xml Edgar Link unprocessable
axsm-20220331_htm.xml Edgar Link completed
axsm-20220331_lab.xml Edgar Link unprocessable
axsm-20220331_pre.xml Edgar Link unprocessable
axsm-ex10_1.htm Edgar Link pending
axsm-ex10_1.pdf Edgar Link pending
axsm-ex31_1.htm Edgar Link pending
axsm-ex31_2.htm Edgar Link pending
axsm-ex32_1.htm Edgar Link pending
axsm-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending